Verition Fund Management
IBB icon

Verition Fund Management’s iShares Biotechnology ETF IBB Stock Holding History

Verition Fund Management’s Portfolio IBB Stock Details IBB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$305K Buy
+1,602
New +$275K ﹤0.01% 1745
2021
Q1 		– Sell
-1,652
Closed -$250K – 1637
2020
Q4 		$250K Buy
+1,652
New +$236K ﹤0.01% 895

Other funds holding IBB

Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
Citigroup
Citigroup New York $303B AUM 53.02% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
BNP Paribas Financial Markets
BNP Paribas Financial Markets Paris, France $289B AUM 60.46% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
Envestnet Asset Management
Envestnet Asset Management Chicago, Illinois $424B AUM 22.96% 1-Year Est. Return
Raymond James Financial
Raymond James Financial St Petersburg, Florida $369B AUM 28.27% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $617B AUM 30.33% 1-Year Est. Return
CB
Commerce Bank Kansas City, Missouri $22.8B AUM 28.56% 1-Year Est. Return

Verition Fund Management's IBB Position: Q2 2026 in Review

Verition Fund Management opened a new position in iShares Biotechnology ETF (IBB) in Q2 2026: 1,602 shares worth $305K. The stake represents ﹤0.01% of the portfolio and ranks #1745 among its holdings. This is a return to the name: Verition Fund Management previously reported a position in IBB as recently as Q4 2020.

Verition Fund Management first reported a position in IBB in Q4 2020 and has held it in 2 quarters since. 960 funds tracked by Wall St. Rank hold IBB as of Q2 2026.

  • Verition Fund Management held 1,602 shares of iShares Biotechnology ETF worth $305K as of Q2 2026.
  • iShares Biotechnology ETF was a new Verition Fund Management position in Q2 2026.
  • iShares Biotechnology ETF made up ﹤0.01% of Verition Fund Management's portfolio in Q2 2026, its #1745 holding.
  • Verition Fund Management first reported a position in iShares Biotechnology ETF in Q4 2020 and has held it in 2 quarters since.
  • 960 funds tracked by Wall St. Rank held iShares Biotechnology ETF as of Q2 2026.

Based on Verition Fund Management's 13F filing for Q2 2026, filed 14 Aug 2026.